Insulet Corp. PODD recently announced positive results from its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) type 2 diabetes pivotal trial. The landmark study assessed the impact of AID ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

Insulet has announced that its Omnipod 5 Automated Insulin Delivery System has been cleared by the US Food and Drug Administration (FDA) for the indication of type 2 diabetes. The company says that ...

As Americans flock to nearby orchards for festive bouts of autumn apple picking, Insulet is celebrating a particularly bountiful stateside Apple harvest itself. The diabetes devicemaker has earned FDA ...

Insulet Corporation PODD continues to gain on solid prospects in the diabetes market. The company is progressing well with respect to its four-pillar strategy. Yet, macroeconomic woes exert ...

Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...

Insulet PODD continues to gain on solid prospects in the diabetes market. The company is progressing well with respect to its four-pillar strategy. Yet, its heavy reliance on the Omnipod System and a ...

The Omnipod 5 System consists of a tubeless wearable Pod, the Omnipod 5 mobile app, and the Dexcom G6 Continuous Glucose Monitoring System. The Food and Drug Administration (FDA) has cleared the ...

Insulet's Q2 revenue of $488M exceeded estimates, driven by strong Omnipod 5 demand and international growth. Insulet raised its full-year revenue forecast to 18%-21% growth, up from the previous ...

BILLERICA, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), ...